Kalbe Farma Tbk PTKLBF:JKT

1,550
10.00 / 0.65%
21.04m
16.54%
0.9836
Latest price in IDRToday's changeShares traded1 year changeBeta
As of Apr 23 2014 08:13 BST.Data delayed by at least 15 minutes.

Consensus recommendation

As of Apr 18, 2014, the consensus forecast amongst 19 polled investment analysts covering PT Kalbe Farma Tbk advises that the company will outperform the market. This has been the consensus forecast since the sentiment of investment analysts improved on Dec 07, 2012. The previous consensus forecast advised investors to hold their position in PT Kalbe Farma Tbk.

Previous recommendations
Last year3 months ago2 months ago4 weeks agoLatest
Mouseover chart recommendation details.
Latest recommendation
Buy8
Outperform4
Hold5
Underperform1
Sell0
No opinion0

Share price forecast

The 13 analysts offering 12 month price targets for PT Kalbe Farma Tbk have a median target of 1,520, with a high estimate of 2,000 and a low estimate of 1,090. The median estimate represents a -1.30% decrease from the last price of 1,540. View Full Financials

High+29.0 %2,000
Med-1.9 %1,520
Low-29.7 %1,090

Dividends

Historical dividend information is not available for Kalbe Farma Tbk PT. View Full Financials

Div growth (TTM)+35.71%
  • Mouseover chart for details.
  • Dividend forecast
  • Quarter 1
  • Quarter 2
  • Quarter 3
  • Quarter 4

Earnings history & estimates

On Oct 29, 2013, PT Kalbe Farma Tbk reported 3rd quarter 2013 earnings of 9.00 per share. This result under-performed the 9.69 expectation of the one analyst following the company but under-performed last year's 3rd quarter results by 80.85%.
The next earnings announcement is expected on Apr 28, 2014. View Full Interim Financials

Average growth rate+88.70%

PT Kalbe Farma Tbk reported annual 2013 earnings of 40.95 per share on Mar 27, 2014. View Full Annual Financials

Average growth rate+21.08%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement

Revenue

PT Kalbe Farma Tbk had 4th quarter 2013 revenues of 4.56bn. This missed the 4.60bn consensus estimate of the 7 analysts following the company. This was 13.53% above the prior year's 4th quarter results. View Full Interim Financials

Average growth rate+4.23%

PT Kalbe Farma Tbk had revenues for the full year 2013 of 16.00bn. This was 17.35% above the prior year's results. View Full Annual Financials

Average growth rate+15.48%
  • Mouseover chart for details.
  • Reported results
  • Forecasts
  • Pos/Neg restatement
© Thomson Reuters Click for restrictions.

All markets data located on FT.com is subject to the FT Terms & Conditions.

All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.

Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.